
04/17/2006
MDB Capital Group Exclusive Placement Agent for $23,000,000 Opexa Therapeutics (OPXA) OfferingSanta Monica, CA V April 17, 2006 X A 23,000,000 unit offering for Opexa Therapeutics ("Opexa") (Symbol V OPXA) was placed with institutional investors at $10.00 per unit, with MDB Capital Group serving as the exclusive Placement Agent. A unit consists of two shares of common stock and a five year redeemable warrant to purchase one shares of its common stock at an exercise price of $6.50/share. Total gross proceeds of the offering were approximately $23,000,000.
About Opexa Therapeutics: Opexa's strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies that will be starting an FDA Phase IIb clinical trial to evaluate effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood.
About MDB Capital Group LLC: MDB Capital Group is a research driven investment bank providing financial services to emerging growth companies, as well as institutional asset management firms, mutual funds, hedge funds and high net worth individuals.
Founded in 1997, MDB provides the following professional services:
MDB is an NASD licensed broker-dealer and a member of the Securities Investor Protection Corporation ("SIPC"). MDB conducts its sales and trading activities in Santa Monica, California.